As the "Third Medical Revolution," Cell and Gene Therapy (CGT) tackles cancer, rare diseases, and genetic disorders at their root by repairing, modifying, or replacing abnormal genes and cells. Begrand maintains a deep focus on the CGT sector, providing a comprehensive suite of process equipment and cleanroom solutions spanning the entire value chain—including cell isolation, activation, gene editing, expansion and culture, viral vector production, and formulation and filling. Our systems are compatible with a wide range of cutting-edge technologies—such as CAR-T, CAR-NK, stem cells, and AAV—and feature automated, closed, and modular designs. By ensuring the high activity, purity, and safety of these "living drugs," we empower our clients to achieve the medical breakthrough of "one treatment, lasting cure."